William Blair and BDA advise Hemovent on its sale to MicroPort for €123m

BDA Partners is pleased to announce Hemovent, a company backed by a consortium of institutional investors led by MIG Capital, advised by William Blair in conjunction with BDA Partners, has been acquired by MicroPort (SEHK Ticker: 0853) for €123m in total consideration (including future milestone payments). The transaction was signed on Aug 6, 2021, with all necessary regulatory approvals granted on Sep 28, 2021, and closed on Oct 13, 2021.

Hemovent, established in 2013 in Aachen, Germany, is a medical device company specializing in developing Extracorporeal Life Support (ECLS) systems. Hemovent’s flagship product, the MOBYBOX® system, is the first fully integrated ECLS system to manage both perfusion and gas exchange in a single device.  It has set a new standard for Extracorporeal Membrane Oxygenation (ECMO) devices in terms of mobility and ease of use.

MicroPort has established its foothold in the critical care sector through its subsidiary MicroPort® Surgery, providing patients with comprehensive medical solutions for cardiac surgery, emergency and critical care. The Hemovent acquisition will further advance MicroPort’s strategy in emergency and critical care, through the combination of Cardiopulmonary Bypass (CPB) with the R&D, manufacturing and commercialization of ECMO products.

Andrew Huntley, Managing Partner and Global Head of Healthcare at BDA Partners, said: “We’re very happy to have helped Hemovent find an ideal strategic partner in China that will take its ground-breaking technology to the next level. The deal reflects our deep knowledge in the medtech sector, extensive Asian strategic and financial sponsor network and seamless execution in global sale processes. This is a great outcome for all parties involved.”

Anthony Siu, Partner, Co-Head of Shanghai at BDA Partners, commented: “This is BDA’s 8^th healthcare M&A transaction involving a Chinese buyer in the last two years. The transaction reaffirms our capability to successfully identify strategic buyers for our global sale processes, leveraging on our strong client network in China and across Asia.  It further demonstrates our ability to navigate through the complexity in executing cross-border transactions for our clients. We expect to see continued strong interest in the healthcare sector from Asian investors.”